301263 泰恩康
已收盘 05-27 15:00:00
资讯
新帖
简况
泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%
证券之星 · 05-21
泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%
泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书
智通财经 · 05-21
泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书
泰恩康拟募资8.7亿谋转型
中国经营网 · 05-16
泰恩康拟募资8.7亿谋转型
泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%
证券之星 · 05-15
泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%
泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资
美股速递 · 05-08
泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资
泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目
证券之星 · 05-08
泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目
每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组
证券之星 · 05-03
每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组
【机构调研记录】东海基金调研美诺华、泰恩康等5只个股(附名单)
证券之星 · 04-29
【机构调研记录】东海基金调研美诺华、泰恩康等5只个股(附名单)
股市必读:泰恩康年报 - 第四季度单季净利润同比增长65.84%
证券之星 · 04-29
股市必读:泰恩康年报 - 第四季度单季净利润同比增长65.84%
图解泰恩康年报:第四季度单季净利润同比增长65.84%
证券之星 · 04-28
图解泰恩康年报:第四季度单季净利润同比增长65.84%
泰恩康最新公告:全资子公司收到吡仑帕奈片药品注册证书
证券之星 · 04-17
泰恩康最新公告:全资子公司收到吡仑帕奈片药品注册证书
泰恩康(301263)披露全资子公司收到马昔腾坦片药品注册证书,4月7日股价上涨1.8%
证券之星 · 04-07
泰恩康(301263)披露全资子公司收到马昔腾坦片药品注册证书,4月7日股价上涨1.8%
泰恩康最新公告:全资子公司收到马昔腾坦片药品注册证书
证券之星 · 04-03
泰恩康最新公告:全资子公司收到马昔腾坦片药品注册证书
4月1日泰恩康涨10.72%,大成积极成长混合A基金重仓该股
证券之星 · 04-01
4月1日泰恩康涨10.72%,大成积极成长混合A基金重仓该股
泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成首例受试者入组,3月26日股价下跌2.35%
证券之星 · 03-26
泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成首例受试者入组,3月26日股价下跌2.35%
泰恩康(301263.SZ):卵磷脂络合碘片(沃丽汀)获药品再注册批准
智通财经 · 03-18
泰恩康(301263.SZ):卵磷脂络合碘片(沃丽汀)获药品再注册批准
股市必读:3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元
证券之星 · 03-16
股市必读:3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元
3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元
证券之星 · 03-13
3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元
股市必读:3月11日泰恩康现2笔折价19.46%的大宗交易 合计成交1449.69万元
证券之星 · 03-12
股市必读:3月11日泰恩康现2笔折价19.46%的大宗交易 合计成交1449.69万元
泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%
证券之星 · 03-02
泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%
加载更多
公司概况
公司名称:
广东泰恩康医药股份有限公司
所属行业:
批发业
上市日期:
2022-03-29
主营业务:
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。
发行价格:
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":25.39,"timestamp":1779865425000,"preClose":25.05,"halted":0,"volume":5162114,"delay":0,"changeRate":0.0136,"floatShares":304000000,"shares":425000000,"eps":0.0604,"marketStatus":"已收盘","change":0.34,"latestTime":"05-27 15:00:00","open":25.13,"high":26.18,"low":24.89,"amount":131000000,"amplitude":0.0515,"askPrice":25.39,"askSize":88,"bidPrice":25.38,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.0604,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779931800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.05,"symbolType":"stock","openAndCloseTimeList":[[1779845400000,1779852600000],[1779858000000,1779865200000]],"highLimit":27.56,"lowLimit":22.55,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"isCdr":false,"pbRate":6.28,"roa":"--","peRate":420.364238,"roe":"1.7%","epsLYR":0.07,"committee":-0.058626,"marketValue":10803000000,"turnoverRate":0.017,"status":0,"floatMarketCap":7708000000},"requestUrl":"/m/hq/s/301263/","defaultTab":"news","newsList":[{"id":"2637938285","title":"泰恩康(301263)披露2025年年度股东会决议公告,5月21日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637938285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637938285?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:16","pubTimestamp":1779358579,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,泰恩康报收于26.43元,较前一交易日下跌0.11%,最新总市值为112.46亿元。公司于近日披露《2025年年度股东会决议公告》。公告显示,广东泰恩康医药股份有限公司于2026年5月20日召开2025年年度股东会,审议通过了《2025年度董事会工作报告》《2025年年度报告》及其摘要、2025年度利润分配及资本公积金转增股本预案、续聘2026年度审计机构、为子公司提供担保额度预计、变更注册资本并修订公司章程等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637383351","title":"泰恩康(301263.SZ)子公司收到和胃整肠丸药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637383351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637383351?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:00","pubTimestamp":1779350421,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康 发布公告,公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的和胃整肠丸《药品注册证书》。2023年7月,公司与泰国李万山药厂两合公司签订《技术转让合同》,由此取得“和胃整肠丸”的全套生产技术及在国内的所有权益。此次“和胃整肠丸”同名同方药注册申请经国家药监局审批通过,标志着该品种的国产化进程顺利落地,“和胃整肠丸”成为公司自有独家品种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635305100","title":"泰恩康拟募资8.7亿谋转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2635305100","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635305100?lang=zh_cn&edition=full","pubTime":"2026-05-16 04:16","pubTimestamp":1778876179,"startTime":"0","endTime":"0","summary":"“泰恩康目前研发需要大量资金,公司有没有融资计划?”5月7日,有投资者在泰恩康(301263.SZ)业绩会上抛出上述问题后,5月8日,泰恩康披露向不特定对象发行可转换公司债券预案,公司拟募资8.7亿元,用于创新药研发、创新药及高端外用制剂产业化建设等四个项目。其中,创新药研发项目拟投入3.51亿元,金额占比最高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605163739368347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033110","title":"泰恩康(301263)披露召开2025年年度股东会提示性公告,5月15日股价下跌0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033110?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:36","pubTimestamp":1778855781,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,泰恩康报收于26.9元,较前一交易日下跌0.41%,最新总市值为114.46亿元。该股当日开盘27.01元,最高27.38元,最低26.74元,成交额达9724.86万元,换手率为1.18%。公司于近日发布《关于召开2025年年度股东会的提示性公告》。公告显示,广东泰恩康医药股份有限公司将于2026年5月20日召开2025年年度股东会,会议采取现场表决与网络投票相结合的方式。股权登记日为2026年5月14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195482505","title":"泰恩康拟发行可转债募资不超过8.7亿元 用于项目投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1195482505","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195482505?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:51","pubTimestamp":1778244707,"startTime":"0","endTime":"0","summary":"广东泰恩康医药股份有限公司宣布,计划通过发行可转换公司债券筹集资金,最高募资额不超过8.7亿元人民币。此次募集资金将专项用于支持公司相关项目的发展建设。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633471459","title":"泰恩康最新公告:拟发行不超8.7亿元可转债用于创新药等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2633471459","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633471459?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:50","pubTimestamp":1778244659,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司拟向不特定对象发行可转换公司债券,募集资金总额不超过8.7亿元(含本数),扣除发行费用后拟用于创新药研发项目、创新药及高端外用制剂产业化建设项目、华铂凯盛制剂生产基地项目及亳州泰恩康现代中药制剂产线建设项目(一期)。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800041117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","301263","BK0250","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632231608","title":"每周股票复盘:泰恩康(301263)CKBA儿童白癜风II期临床将首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2632231608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632231608?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:34","pubTimestamp":1777768451,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,泰恩康报收于28.85元,较上周的28.53元上涨1.12%。本周关注点来自机构调研要点:儿童白癜风2-12岁适应症II期临床预计2026年上半年完成首例入组。②儿童白癜风2-12岁适应症II期临床试验已通过伦理审核,预计2026年上半年完成首例入组,目标2027年下半年读出数据。CKB乳膏已取得国内首张 2-12岁儿童非节段型白癜风 II期临床试验批件,短期内市场处于空白状态,公司有望成为首个获批儿童白癜风外用药物的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631427558","title":"【机构调研记录】东海基金调研美诺华、泰恩康等5只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631427558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631427558?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:12","pubTimestamp":1777421578,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月28日披露的机构调研信息,东海基金近期对5家上市公司进行了调研,相关名单如下:1)美诺华 调研纪要:公司主业具备坚实基础,呈现持续增长趋势,得益于过去五年布局及大客户合作推进。JH389研发投入基本完成,后续销售费用视商业化方案而定;小核酸研发分阶段投入,不构成财务压力。4)迈普医学 调研纪要:公司以“成为高性能医疗器械全球领先企业”为愿景,持续推进国内外市场布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900026053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603538","301263","BK0250","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537306","title":"股市必读:泰恩康年报 - 第四季度单季净利润同比增长65.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537306","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537306?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:55","pubTimestamp":1777416945,"startTime":"0","endTime":"0","summary":"当日关注点来自:泰恩康2025年归母净利润同比下降73.54%,但第四季度亏损收窄,同比上升65.84%。股本股东变化股东户数变动近日泰恩康披露,截至2026年3月31日公司股东户数为1.3万户,较12月31日减少110.0户,减幅为0.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900016959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630115573","title":"图解泰恩康年报:第四季度单季净利润同比增长65.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630115573","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630115573?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:58","pubTimestamp":1777312721,"startTime":"0","endTime":"0","summary":"证券之星消息,泰恩康2025年年报显示,当年度公司主营收入6.75亿元,同比下降6.4%;归母净利润2863.29万元,同比下降73.54%;扣非净利润3036.91万元,同比下降71.36%;其中2025年第四季度,公司单季度主营收入1.49亿元,同比上升0.27%;单季度归母净利润-277.23万元,同比上升65.84%;单季度扣非净利润-100.98万元,同比上升86.68%;负债率27.97%,投资收益70.42万元,财务费用1010.42万元,毛利率54.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800005416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628271733","title":"泰恩康最新公告:全资子公司收到吡仑帕奈片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628271733","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628271733?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:07","pubTimestamp":1776416859,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司全资子公司安徽泰恩康制药有限公司于近日收到国家药监局签发的吡仑帕奈片《药品注册证书》。该药品为化学药品4类,规格包括2mg和4mg,用于成人和12岁及以上儿童癫痫部分发作患者的辅助治疗,属于第二类精神药品。截至目前,国内共有9家企业获得该药品注册批件。公司表示,该产品未来的具体销售情况可能受到行业政策、市场环境等因素影响,具有不确定性,敬请广大投资者审慎决策,注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700031807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625693954","title":"泰恩康(301263)披露全资子公司收到马昔腾坦片药品注册证书,4月7日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693954","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625693954?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:33","pubTimestamp":1775554397,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,泰恩康报收于27.15元,较前一交易日上涨1.8%,最新总市值为115.52亿元。广东泰恩康医药股份有限公司全资子公司山东华铂凯盛生物科技有限公司近日收到国家药品监督管理局签发的马昔腾坦片《药品注册证书》,药品名称为马昔腾坦片,剂型为片剂,规格为10mg,注册分类为化学药品4类,上市许可持有人为山东华铂凯盛生物科技有限公司。审批结论为符合药品注册有关要求,批准注册。目前国内已有8家企业取得该药品注册批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624065229","title":"泰恩康最新公告:全资子公司收到马昔腾坦片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624065229","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624065229?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:40","pubTimestamp":1775216424,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称,公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药监局签发的马昔腾坦片《药品注册证书》。该药品为化学药品4类,规格10mg,用于治疗肺动脉高压,以延缓疾病进展。截至目前,国内共有8家企业获得该药品注册批件。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300038345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595397","title":"4月1日泰恩康涨10.72%,大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595397?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:19","pubTimestamp":1775031564,"startTime":"0","endTime":"0","summary":"证券之星消息,4月1日泰恩康涨10.72%,收盘报28.61元,换手率3.74%,成交量11.36万手,成交额3.17亿元。重仓泰恩康的公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.87亿元,最新净值1.082,较上一交易日下跌0.92%,近一年上涨30.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622580068","title":"泰恩康(301263)披露控股子公司CKBA乳膏玫瑰痤疮适应症IIa期临床试验完成首例受试者入组,3月26日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622580068","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622580068?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:22","pubTimestamp":1774516961,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,泰恩康报收于24.89元,较前一交易日下跌2.35%,最新总市值为105.91亿元。该股当日开盘25.48元,最高25.76元,最低24.8元,成交额达7738.59万元,换手率为1.01%。公告显示,公司控股子公司江苏博创园生物医药科技有限公司开展的CKBA乳膏治疗玫瑰痤疮适应症IIa期临床试验已完成首例受试者入组。该试验旨在评价CKBA乳膏治疗丘疹脓疱型玫瑰痤疮的有效性与安全性,目前受试者招募和筛选工作正加快推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620323235","title":"泰恩康(301263.SZ):卵磷脂络合碘片(沃丽汀)获药品再注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620323235","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620323235?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:29","pubTimestamp":1773822572,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰恩康(301263.SZ)公告,公司收到国家药品监督管理局核准签发的“沃丽汀”卵磷脂络合碘片《药品再注册批准通知书》。“沃丽汀”卵磷脂络合碘片是目前治疗眼底疾病的唯一口服的有机碘片。公司自1999年开始代理销售沃丽汀,作为沃丽汀的中国唯一总代理全权负责其在国内的推广、销售,拥有完整的销售定价权并掌控相关的销售渠道和客户资源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰恩康(301263.SZ):卵磷脂络合碘片(沃丽汀)获药品再注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619088107","title":"股市必读:3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619088107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619088107?lang=zh_cn&edition=full","pubTime":"2026-03-16 01:40","pubTimestamp":1773596417,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,泰恩康报收于29.03元,上涨0.8%,换手率1.47%,成交量4.47万手,成交额1.3亿元。来自:泰恩康当日出现折价20.63%的大宗交易,合计成交571.39万元,引发市场关注。交易信息汇总资金流向3月13日主力资金净流出1788.9万元;游资资金净流入1161.8万元;散户资金净流入627.1万元。大宗交易3月13日泰恩康现1笔折价20.63%的大宗交易,合计成交571.39万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600000629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619606681","title":"3月13日泰恩康现1笔折价20.63%的大宗交易 合计成交571.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619606681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619606681?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393123,"startTime":"0","endTime":"0","summary":"证券之星消息,3月13日泰恩康发生大宗交易,交易数据如下:大宗交易成交价格23.04元,相对当日收盘价折价20.63%,成交24.8万股,成交金额571.39万元,买方营业部为中国银河证券股份有限公司深圳分公司,卖方营业部为长城证券股份有限公司青岛龙城路证券营业部。近三个月该股共发生6笔大宗交易,合计成交1.7万手,折价成交6笔。截至2026年3月13日收盘,泰恩康报收于29.03元,上涨0.8%,换手率1.47%,成交量4.47万手,成交额1.3亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618927816","title":"股市必读:3月11日泰恩康现2笔折价19.46%的大宗交易 合计成交1449.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618927816","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618927816?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:42","pubTimestamp":1773250933,"startTime":"0","endTime":"0","summary":"截至2026年3月11日收盘,泰恩康报收于29.4元,下跌0.68%,换手率0.57%,成交量1.74万手,成交额5132.78万元。交易信息汇总资金流向3月11日主力资金净流出377.98万元;游资资金净流入529.73万元;散户资金净流出151.75万元。大宗交易3月11日泰恩康现2笔折价19.46%的大宗交易,合计成交1449.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200001036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355236","title":"泰恩康(301263)披露全资子公司五款药品中选国家集采药品接续采购公告,3月2日股价下跌3.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355236?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:52","pubTimestamp":1772463136,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,泰恩康报收于30.09元,较前一交易日下跌3.8%,最新总市值为128.03亿元。公司于2026年3月2日发布《关于全资子公司部分药品中选国家集采药品接续采购的公告》。公告显示,泰恩康全资子公司山东华铂凯盛生物科技有限公司参加国家组织集采药品协议期满品种接续采购,其五款药品包括他达拉非片、盐酸达泊西汀片、盐酸普拉克索缓释片、阿加曲班注射液和奥硝唑注射液成功中选。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779871459066,"stockEarnings":[{"period":"1week","weight":-0.075},{"period":"1month","weight":-0.122},{"period":"3month","weight":-0.223},{"period":"6month","weight":-0.1332},{"period":"1year","weight":-0.0461},{"period":"ytd","weight":-0.1359}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0004},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.2386},{"period":"ytd","weight":0.0445}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"12996人(较上一季度减少0.84%)","perCapita":"28031股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"51059万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药,2020年8月正式投放市场,目前在达泊西汀院外渠道市场稳居头部地位,尤其在线下零售市场形成显著品牌优势。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}